The effect of cancer chemotherapeutic agents on fibrin formation and stabilization in vitro.
D000970:Antineoplastic Agents / Q000494:pharmacology*; D001215:Asparaginase / Q000494:pharmacology; D001780:Blood Coagulation Tests; D003520:Cyclophosphamide / Q000494:pharmacology; D003561:Cytarabine / Q000494:pharmacology; D003609:Dactinomycin / Q000494:pharmacology; D003630:Daunorubicin / Q000494:pharmacology; D004317:Doxorubicin / Q000494:pharmacology; D004553:Electric Conductivity; D005176:Factor XIII; D005337:Fibrin / Q000096:biosynthesis*; D005342:Fibrinolysis / Q000187:drug effects*; D005472:Fluorouracil / Q000494:pharmacology; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007093:Imidazoles / Q000494:pharmacology; D066298:In Vitro Techniques; D008466:Mechlorethamine / Q000494:pharmacology; D008727:Methotrexate / Q000494:pharmacology; D008854:Microscopy, Electron; D009588:Nitrogen Mustard Compounds / Q000494:pharmacology; D012995:Solubility; D014226:Triazenes / Q000494:pharmacology; D014508:Urea; D014747:Vinblastine / Q000494:pharmacology; D014750:Vincristine / Q000494:pharmacology
D000970:Antineoplastic Agents; D007093:Imidazoles; D009588:Nitrogen Mustard Compounds; D014226:Triazenes; D003561:Cytarabine; D003609:Dactinomycin; D008466:Mechlorethamine; D014750:Vincristine; D014747:Vinblastine; D004317:Doxorubicin; D003520:Cyclophosphamide; D014508:Urea; D005337:Fibrin; D005176:Factor XIII; D001215:Asparaginase; D005472:Fluorouracil; D008727:Methotrexate; D003630:Daunorubicin